| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CORT | Common Stock | Award | $15.8K | +478 | +9.98% | $33.10 | 5.27K | Sep 1, 2023 | Direct | F1, F2, F3 |
| transaction | CORT | Common Stock | Award | $0 | +478 | +9.08% | $0.00 | 5.74K | Sep 1, 2023 | Direct | F3, F4 |
| Id | Content |
|---|---|
| F1 | The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on September 1, 2023. |
| F2 | In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. |
| F3 | Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,472 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| F4 | Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. |
The power of attorney under which this form was signed is on file with the Commission.